These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23943614)

  • 21. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher order structures of Adalimumab, Infliximab and their complexes with TNFα revealed by electron microscopy.
    Tran BN; Chan SL; Ng C; Shi J; Correia I; Radziejewski C; Matsudaira P
    Protein Sci; 2017 Dec; 26(12):2392-2398. PubMed ID: 28940886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
    Bacquet-Deschryver H; Jouen F; Quillard M; Ménard JF; Goëb V; Lequerré T; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role for tumor necrosis factor-alpha inhibitors and especially thalidomide in dermatology?
    Moschella SL
    Skinmed; 2005; 4(1):19-30; quiz 31-2. PubMed ID: 15654161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
    Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
    J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.
    Shealy DJ; Cai A; Staquet K; Baker A; Lacy ER; Johns L; Vafa O; Gunn G; Tam S; Sague S; Wang D; Brigham-Burke M; Dalmonte P; Emmell E; Pikounis B; Bugelski PJ; Zhou H; Scallon BJ; Giles-Komar J
    MAbs; 2010; 2(4):428-39. PubMed ID: 20519961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [TNFα blocking agents and sarcoidosis: an update].
    Toussirot E; Pertuiset E
    Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNFalpha blockade in human diseases: an overview of efficacy and safety.
    Lin J; Ziring D; Desai S; Kim S; Wong M; Korin Y; Braun J; Reed E; Gjertson D; Singh RR
    Clin Immunol; 2008 Jan; 126(1):13-30. PubMed ID: 17916445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
    Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
    J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.
    Lim H; Lee SH; Lee HT; Lee JU; Son JY; Shin W; Heo YS
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
    Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
    J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Are there differences among anti-TNFα biological drugs?].
    Valesini G
    Reumatismo; 2005; 57(4 Suppl):1-2. PubMed ID: 16385348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoriasis and psoriasiform lesions induced by TNFα antagonists: the experience of a tertiary care hospital from northern Spain.
    López-Robles A; Queiro R; Alperi M; Alonso S; Riestra JL; Ballina J
    Rheumatol Int; 2012 Dec; 32(12):3779-83. PubMed ID: 22187056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.